Although T-DM1 was highly effective in HER2-positive gastric cancer (GC) cells and xenografts, the GATSBY study conferred that T-DM1 was not superior to taxane in patients with previously treated HER2-positive AGC (Thuss-Patience et al., 2017). Here, ERBB2 is linked to gastric cancer.